SHR1459 tablet + Efavirenz tablet
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Tumors
Conditions
B-cell Tumors
Trial Timeline
Nov 4, 2022 → Jan 27, 2023
NCT ID
NCT05560360About SHR1459 tablet + Efavirenz tablet
SHR1459 tablet + Efavirenz tablet is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for B-cell Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT05560360. Target conditions include B-cell Tumors.
What happened to similar drugs?
3 of 20 similar drugs in B-cell Tumors were approved
Approved (3) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05560360 | Phase 1 | Completed |
Competing Products
20 competing products in B-cell Tumors